Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Digestive and Liver Disease Année : 2023

Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study

Résumé

Background: There is no robust predictor of response to chemotherapy (CT) in unresectable pancreatic adenocarcinomas (UPA). The objective of the KRASCIPANC study was to analyze the kinetics of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) as a predictor of response to CT in UPA.
Methods: Blood samples were collected just before first CT and at day 28. The primary endpoint was the kinetics of KRAS-mutated ctDNA by digital droplet PCR between D0 and D28 as a predictor of progression-free survival (PFS).
Results: We analyzed 65 patients with a KRAS-mutated tumor. A high level of cfDNA and KRAS-mutated ctDNA at D0, as well as the presence of KRAS-mutated ctDNA at D28, were strongly associated with lower centralized disease control rate (cDCR), shorter cPFS and OS in multivariate analysis. A score combining cfDNA level at diagnosis ≥ or <30 ng/mL and presence or not of KRAS-mutated ctDNA at D28 was an optimal predictor of cDCR (OR=30.7, IC95% 4.31-218 P=.001), PFS (HR=6.79, IC95% 2.76-16.7, P<.001) and OS (HR=9.98, IC95% 4.14-24.1, P<.001).
Conclusion: A combined score using cfDNA level at diagnosis and KRAS-mutated ctDNA at D28 is strongly associated with patient survival/response to chemotherapy in UPA.
Fichier principal
Vignette du fichier
Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy_The KRASCIPANC prospective study.pdf (1.13 Mo) Télécharger le fichier
Origine Publication financée par une institution
Licence

Dates et versions

hal-04648773 , version 1 (18-07-2024)

Licence

Identifiants

Citer

Camille Evrard, Pierre Ingrand, Tristan Rochelle, Marine Martel, Gaëlle Tachon, et al.. Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study. Digestive and Liver Disease, 2023, 55 (11), pp.1562-1572. ⟨10.1016/j.dld.2023.03.011⟩. ⟨hal-04648773⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More